摘要
目的利用网络药理学和细胞实验探讨艾迪注射液治疗卵巢癌的关键分子靶点及可能的作用机制。方法通过中药系统药理学数据库与分析平台(Troditional Chinese Medicine Systems Pharmacology Database and Analysis Platform,TCMSP)数据库筛选艾迪注射液中中药的活性成分及作用靶点,并筛选卵巢癌异常表达的基因,取交集后获得艾迪注射液作用于卵巢癌的可能靶点。接着对可能靶点进行蛋白质互作网络分析、构建药物-化合物-靶点网络和富集分析。进一步筛选靶点,对与卵巢癌预后相关的关键基因进行实验验证,用50mg/ml艾迪注射液处理卵巢癌细胞后利用CCK-8实验观察细胞增殖能力,实时荧光定量聚合酶链反应技术检测核心靶基因的表达。结果筛选到艾迪注射液作用于卵巢癌的可能靶点共13个。这些靶点主要富集于细胞凋亡、铂耐药和白细胞介素-17等肿瘤发生、发展密切相关的信号通路。13个基因中,与卵巢癌预后相关的关键基因为细胞间紧密连接蛋白4(claudin 4,CLDN4)、分泌性白细胞蛋白酶抑制因子(secretory leukocyte peptidase inhibitor,SLPI)和杆状病毒IAP重复序列包含5(baculoviral IAP repeat containing 5,BIRC5)。细胞实验发现,艾迪注射液能显著抑制卵巢癌细胞增殖,促进卵巢癌保护性靶点BIRC5的表达,并显著下降卵巢癌危险因素CLDN4和SLPI的水平。结论艾迪注射液可能是通过影响CLDN4、SLPI、BIRC5这3个核心靶点的表达来实现多成分、多靶点、多途径的抗卵巢癌和联合化疗的增效减毒作用。
Objective To explore the key molecular targets and possible mechanisms of Aidi injection in the treatment of ovarian cancer using network pharmacology and cell experiments.Methods TCMSP database was used to screen the active ingredients and targets of Aidi injection,and the abnormal expressed genes of ovarian cancer were screened,and the possible targets of Aidi injection in ovarian cancer were obtained after intersection analysis.Then,protein-protein interaction analysis,drug-compact-target network construction and enrichment analysis of possible targets were performed.The target was further screened,and the key genes related to the prognosis of ovarian cancer were experimentally verified.After treated with 50mg/ml Aidi injection,the cell proliferation ability was observed by CCK-8 assay,and the expression of core target genes was detected by real-time quantitative polymerase chain reaction.Results A total of 13 possible targets of Aidi injection in ovarian cancer were screened.These targets were mainly enriched in signaling pathways closely related to the occurrence and development of tumors,such as apoptosis,platinum resistance and interleukin-17.Among the 13 genes,claudin 4(CLDN4),secretory leukocyte peptidase inhibitor(SLPI)and baculoviral IAP repeat containing 5(BIRC5)were associated with the prognosis of ovarian cancer.Cell experiments showed that Aidi injection significantly inhibited the proliferation of ovarian cancer cell,promoted the expression of BIRC5,a protective target of ovarian cancer,while significantly decreased the levels of ovarian cancer risk factors CLDN4 and SLPI.Conclusion Aidi injection may achieve multi-component,multi-target and multi-pathway anti-ovarian cancer and combination chemotherapy by affecting the expression of CLDN4,SLPI and BIRC5.
作者
邓志敏
吴玛丽
代芳芳
程艳香
DENG Zhimin;WU Mali;DAI Fangfang(Department of Obstetrics and Gynecology,Renmin Hospital of Wuhan University,Hubei 430060,China)
出处
《医学研究杂志》
2024年第2期40-50,61,共12页
Journal of Medical Research
基金
国家自然科学基金资助项目(面上项目)(82071655)
湖北省科技厅重点研发计划项目(2020BCB023)。
关键词
艾迪注射液
卵巢癌
细胞增殖
网络药理学
Aidi injection
Ovarian cancer
Cell proliferation
Network pharmacology
